Advancing Human-Relevant Systems to Reduce Reliance on Animal Models
Integrated • Predictive • Translational
Accelerating Smarter, More Human-Relevant Medicine
About NAMina Bio
Building the infrastructure for human-relevant translational research
NAMina Bio is a human-relevant translational intelligence platform operating at the intersection of biology, engineering, and computation.
We integrate organoids, 3D bioprinting, fluidic systems, and AI-driven analytics into unified workflows designed to generate predictive, decision-ready insights across the preclinical development lifecycle.
Our approach addresses a critical limitation in drug development: the lack of scalable, human-relevant systems capable of informing translational decisions with precision.
Aligned with the FDA Modernization Act 2.0 and emerging New Approach Methodologies (NAMs), NAMina is building the translational architecture required to reduce reliance on low-predictive animal models and accelerate clinically relevant discovery.
Founder & Vision
Building the future of human-relevant translational science
NAMina Bio was founded on a clear conviction: the future of drug development will be defined by human-relevant systems capable of generating predictive, decision-ready insights.
Through experience in cancer biology, translational research, and advanced experimental platforms, a fundamental limitation became evident: not the absence of technologies, but the lack of integration between them.
Today’s preclinical landscape remains fragmented, with powerful tools operating in isolation and limited ability to inform translational decisions in a coherent, scalable way.
NAMina was created to address this gap.
By integrating organoids, 3D bioprinting, microphysiological systems, and AI-driven analytics into a unified architecture, NAMina transforms experimental complexity into structured, decision-ready intelligence.
This approach reflects a broader shift across the industry, one increasingly aligned with emerging regulatory frameworks and the adoption of New Approach Methodologies (NAMs), where human biological relevance and fit-for-purpose validation are becoming central to innovation.
The long-term vision is to establish NAMina as the infrastructure layer for translational research, enabling more predictive science, more efficient development, and ultimately more meaningful outcomes for patients.
NAMina reflects both a scientific and personal commitment to advancing research that is more predictive, ethical, and clinically relevant.
For Investors
For investors interested in NAMina’s platform, validation strategy, and active programs:
Paola Dama, PhD
Founder & CEO, NAMina Bio
Paola Dama is a cancer biologist and translational scientist with expertise in molecular oncology, non-coding RNA biology, and immunotherapy. Her research has focused on understanding the mechanisms underlying cancer progression, therapeutic resistance, and immune response, with particular emphasis on translational applications in oncology.
She has contributed to multiple peer-reviewed publications spanning CAR-T cell therapies, microRNA-based regulation, and biomarker discovery, where she has played key roles in study design, data analysis, and scientific development.
Through her academic and translational research experience, she has worked across complex experimental systems, contributing to the development of more predictive and clinically relevant models of human disease.
She is the founder of NAMina Bio, where she is building an integrated translational architecture that connects advanced biological systems, engineering platforms, and AI-driven analytics into a unified decision framework.
Her work aligns with the emerging shift toward New Approach Methodologies (NAMs), with the goal of enabling more predictive, efficient, and human-relevant drug development.
Paola is driven by a long-term vision to redefine preclinical research — moving from fragmented experimentation toward integrated, human-relevant intelligence.
Validation & Traction
Demonstrating the foundation of a human-relevant translational platform
NAMina Bio has achieved early validation through scientific collaboration, data generation, and platform integration across multiple domains.
Initial work includes the development and analysis of advanced 3D tumor models, demonstrating the ability to generate physiologically relevant insights and drug response patterns aligned with clinical exposure ranges.
In parallel, NAMina has established strategic collaborations integrating AI-driven analytics, translational data interpretation, and experimental platform design.
Key milestones include:
• Scientific collaboration and manuscript development with Real Research (PDAC models)
• Accepted abstract at ISPOR, in collaboration with Kolate AI
• Development of pilot programs across oncology, metabolic profiling, and translational validation workflows
• Integration of multi-technology platforms including organoids, bioprinting, and fluidic systems
These activities represent the initial foundation of NAMina’s Translational Architecture Layer™, demonstrating both scientific feasibility and commercial potential.
Ecosystem and Strategic Collaborations
